alexa Glycyrrhizic Acid Mitigates 2nd Round Radiotherapy-Indu
ISSN: 2472-1018

Journal of Lung Diseases & Treatment
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Glycyrrhizic Acid Mitigates 2nd Round Radiotherapy-Induced Severe Lung Injury: A Case Report

Zhang W1, Hong J1, Lin J1, Okunieff P2 and Zhang L1,2*

1Fujian Platform for Medical Research at First Affiliated Hospital; Fujian key Lab of ; Individualized Active Immunotherapy; Key Lab of Radiation Biology of Fujian Province Universities, Fuzhou, China

2Department of Radiation Oncology, University of Florida, Gainesville, FL, USA

*Corresponding Author:
Lurong Zhang
Fujian Key Lab of Individualized Active Immunotherapy and Key Lab of Radiation Biology
Department of Radiation Biology
Fujian Universities
Fuzhou, China
E-mail: [email protected] or [email protected]

Received Date: June 19, 2017; Accepted Date: June 23, 2017; Published Date: July 07, 2017

Citation: Zhang W, Hong J, Lin J, Okunieff P, Zhang L (2017) Glycyrrhizic Acid Mitigates 2nd Round Radiotherapy-Induced Severe Lung Injury: A Case Report. Lung Dis Treat 3:125. doi: 10.4172/2472-1018.1000125

Copyright: © 2017 Zhang W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Irradiation (IR) has become more important and effective therapeutic approach for cancer in chest (lung, breast and esophagus), however, IR-induced pneumonitis/fibrosis is still the bottle-neck for using higher IR dose to more effectively eradicate cancer cells, since there is no drug to treat the companion IR-injury toxicity. Glycyrrhizic Acid (GLA) has been used to treat hepatitis and liver fibrosis for almost 3 decades in Asia. It has no lethal dose in animal and no obvious side effect in human, which allows for 2 to 3 months use to imitate chronic fibrosis. Here we report for the first time that while GLA was used to treat the liver damage caused by chemotherapy, it presented a surprising mitigation effect on a 2nd round IR treatment-induced severe lung injury in a recurrent stage B (T2N3M0) lung cancer patient who had severe pneumonitis during the 1st round IR therapy. Combined with the fact that GLA effectively mitigates IR induced pneumonitis/fibrosis in animal model, we conclude that GLA is a potential good candidate to be developed as anti-IR lung injury drug.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version